Upcoming conference highlights barriers in prescribing PCSK9 inhibitors

The National Lipid Association Clinical Lipid Update will feature a symposium on challenges in prescribing PCSK9 inhibitors.

The symposium, to be held Feb. 24 in Phoenix, is based on the NLA-conducted survey of prescribing and nonprescribing providers on their experiences with the PCSK9 inhibitor approval process.

According to an NLA press release, the data presented will include:

What providers do before prescribing PCSK9 inhibitor therapy;
What thresholds providers use when treating familial hypercholesterolemia and atherosclerotic CVD;
Whether providers are treating to achieve cholesterol goals or statin dose;
How providers are handling statin intolerance; and
Whether providers are using high-intensity statin therapy.

The presentation will be led by Jerome D. Cohen, MD, FNLA, from St. Louis University School of Medicine, Terry A. Jacobson, MD, FNLA, from Emory University, and Kevin C. Maki, PhD, FNLA, from Midwest Center for Metabolic and Cardiovascular Research, Glen Ellyn, Illinois.

Also at the NLA Clinical Lipid Update, Jennifer G. Robinson, MD, FNLA, a professor in the departments of epidemiology and medicine at the University of Iowa, will present on unhealthy lifestyle habits and risk factors of atherosclerotic CVD.

Other notable experts including Antonio M. Gotto, Jr., MD, FNLA, from Weill Cornell Medical College, Benjamin J. Ansell, MD, FNLA, from the David Geffen School of Medicine at UCLA, and Sergio Fazio, MD, PhD, FNLA, from Oregon Health and Science University, Portland, will be presenting at the event, according to the release.

For more information:

NLA Clinical Lipid Update. www.lipid.org/springclu.